Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tax expenses hurt Lupin's profit in FY12, but sales up 22% on growth in core markets

This article was originally published in Scrip

Executive Summary

Lupin has reported a 22% increase in net sales to Rs69.59 billion ($1.29 billion) for the year ended March 2012 backed by strong growth across its key geographies of the US, Japan and India, but tax expenses took the sheen off profits during the year. Net profits increased marginally to Rs8.67 billion as compared with Rs8.62 billion, largely due to a 168.3% increase in tax outflows to Rs3.08 billion on account of an increase in effective tax rates and tax on inventories shipped to overseas subsidiaries for new launches. Profits in the last quarter declined by 31% to Rs1.56 billion on account of tax expenses.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC017326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel